Treatment Of Central Nervous Diseases Research Articles

In Vitro Application of Langmuir Monolayer Model: The interfacial Behavior of Myelin Basic Protein with a Plasma Membrane Model.

The stability and compactness of myelin structure and brain homeostasis depend on MBP and glial cell plasma membrane interactions. In order to get more detailed mechanisms of this interaction, the MBP of different concentrations interacting with plasma membrane (POPC/POPE/POPS/Cholesterol (Chol)) model to form bionic membrane was studied by atomic force microscopy (AFM) and Langmuir monolayer technology. The surface pressure(π)-area(A) curve is analyzed by the elastic modulus ([Formula: see text]) and two-dimensional virial equation of state (2D-VES), and the second virial coefficient of the interaction between MBP and plasma membrane molecules was calculated. (i) According to two-dimensional virial equation, it could be analyzed that with the increase of MBP concentration in the subphase, the value of the second virial coefficient increases also, which indicates that MBP is absorbed into lipid membrane of the plasma membrane model at low surface pressure and that the interaction between the molecules is spatial repulsive force, and (ii) in the monolayers with MBP, resulting in an increasing mean molecular area and monolayer stability due to hydrophobic and electrostatic interactions between the positively charged MBP with hydrophobic residues and negatively charged POPS and neutral lipid (POPC, POPE). AFM surface topographic results correspond to the results of the curve analysis, indicating that MBP of different concentrations has significant influences on alignment and conformation of plasma membrane, which is of great medical value and biological significance to the application of interaction between MBP and myelin lipid membrane in treatment of central nervous diseases. Adsorption model of interaction between MBP and plasma membrane model.

PO-1841: Efficacy of a new dedicated immobilization device for treatment of Central Nervous disease

PO-1841: Efficacy of a new dedicated immobilization device for treatment of Central Nervous disease

Research progress on traditional Chinese medicine in preventing and treating cerebral ischemia injury based on "nose-brain" pathway

Due to the increasing incidence of central nervous system diseases,especially the increasing incidence and mortality of stroke,brain-targeted drug delivery has attached more and more attention. Nasal administration,as one of the ways of brain-targeted administration,can effectively make the drug delivered to the brain in a targeted way after by passing the blood-brain barrier,providing a new idea for the treatment of central nervous system diseases. Therefore,it is a promising administration way. In recent years,the treatment of encephalopathy by nasal administration of traditional Chinese medicine has become a hot topic in the research of traditional Chinese medicine. Ischemic stroke is one of the most important diseases endangering human health. Nasal administration has a history of thousands of years in treatment of stroke. Modern medical research has proved that there is a subtle connection between the nasal cavity and the brain,and the complex and ingenious structure of the nasal cavity provides the possibility for drugs delivery to the brain through the nose. Drug administration through nasal cavity has obvious advantages in treatment of central nervous system diseases represented by ischemic stroke. Nasal administration is characterized by non-invasion,low infection,rapid absorption and brain targeting. The author will expound the theoretical basis of brain targeting of nasal administration from the aspects of anatomy and physiology,and summarize the transport pathway of drugs through the nose into the brain,the in vitro and in vivo experimental research basis of the " nose-brain"pathway,and the clinical nasal administration of traditional Chinese medicine to prevent cerebral ischemia. It provides a reference for better research of drugs to prevent and treat cerebral ischemia injury through the " nose-brain"pathway and lays a foundation for further research of the " nose-brain" pathway.

Retrospect and prospect of the laboratory examination of cerebrospinal fluid

Laboratory tests of cerebrospinal fluid has a long history and multiple service items. It has a positive guiding value in the diagnosis and treatment of central nervous system diseases. With the deepening of people′s understanding of the nervous system diseases, the examination items have developed from single to diversity, from the initial medical examination to biochemistry, molecular biology exams, from the cell, protein level to the gene, molecular level. The main tests include morphology, protein and molecular test levels.This artide will give a systematic introduction of the test items to make readers form a whole understanding of the development process of cerebrospinal fluid laboratory examination.(Chin J Lab Med, 2017, 40: 911-915) Key words: Cerebrospinal fluid; Clinical laboratory techniques; Biological markers; Retrospective studies

Neuroprotective effects of rhynchophylline against ischemic brain injury via regulation of the Akt/mTOR and TLRs signaling pathways.

Rhynchophylline (Rhy) is an alkaloid isolated from Uncaria which has long been recommended for the treatment of central nervous diseases. In our study, the neuroprotective effect of Rhy was investigated in a stroke model, namely permanent middle cerebral artery occlusion (pMCAO). Rats were injected intraperitoneally once daily for four consecutive days before surgery and then received one more injection after surgery. The protein and mRNA levels of p-Akt, p-mTOR, apoptosis-related proteins (p-BAD and cleaved caspase-3), TLR2/4/9, NF-κB, MyD88, BDNF and claudin-5 were examined. Following pMCAO, Rhy treatment not only ameliorated neurological deficits, infarct volume and brain edema, but also increased claudin-5 and BDNF expressions (p < 0.05). Moreover, Rhy could activate PI3K/Akt/mTOR signaling while inhibiting TLRs/NF-κB pathway. Wortmannin, a selective PI3K inhibitor, could abolish the neuroprotective effect of Rhy and reverse the increment in p-Akt, p-mTOR and p-BAD levels. In conclusion, we hypothesize that Rhy protected against ischemic damage, probably via regulating the Akt/mTOR pathway.

Modified Bone Marrow Stromal Cells Therapy for Central Nervous System Disorders

This article concluded our serial studies on the therapeutic protective effects of modified bone marrow stromal cells on central nervous injury. Hope this will provide a prelusion of transition of central nervous disease treatment from experimental treatment to the idea of clinical application.

Increased compactibility of acetames after roll compaction

A common technique for manufacturing granules in a continuous way is the combination of roll compaction and subsequent milling. Roll compaction can considerably impact tableting performance of a material. The purpose of this study was to investigate the influence of roll compaction/dry granulation on the compaction behavior of acetames, a class of active pharmaceutical substances, which are mainly used for the treatment of central nervous diseases. Some representatives of acetames were roll compacted and then compressed into tablets. Compactibility of granules was compared with the compaction behavior of the directly compressed drug powders. In contrast to many other materials, the roll compaction step induced an increase in compactibility for all investigated acetames. Specific surface areas of the untreated and the roll compacted drugs were determined by nitrogen adsorption. The raise in compactibility observed was accompanied by an increase in specific surface area during roll compaction.

Research progress in mesenchymal stem cell and blood-brain barrier permeability

Mesenchymal stem cells(MSCs), which can be introduced in brain tissue by the strategies of brain parenchyma, blood and neurolymph transplantation, to repair tissue injury and promote functional recovery of neural system, have been considered as the ideal seed cells for the treatment of central nervous system diseases. However, as the special structure exists in the blood-brain barrier, study on correlation between MSCs and blood-brain barrier permeability will make it possible for more MSCs to pass the barrier to perform the treatment. This paper gives a review on the latest research development in the field. Key words: Mesenchymal stem cells; Blood-brain barrier; Permeability; Vitro model

Recognition and management of systemic lupus erythematosus.

Systemic lupus erythematosus (SLE) is an inflammatory systemic disease that causes organ damage by the deposition of autoantibodies and complement activating immune complexes or by vascular occlusion due to procoagulant states associated with antiphospholipid antibodies. The vast majority of cases occur in women of childbearing age. SLE is diagnosed on the basis of its clinical manifestations and the demonstration of characteristic immunological phenomena, especially anti-nuclear antibodies. The prognosis in SLE has shown a distinct improvement over recent decades, the 5-year survival rate now approaching or exceeding 90%. The 15-year survival rate of 63 to 79%, on the other hand, underscores the need for further advances in diagnosis and treatment of the disease. Management of the disease includes regular monitoring of disease activity, avoidance of predisposing factors and close supervision of therapy. Drug therapy is guided by the activity and severity of the leading organ manifestations and ranges from nonsteroidal antirheumatic drugs to intensive treatment with cytotoxic agents. Corticosteroids remain irreplaceable for the control of acute flares. Antimalarials and azathioprine are important long term drugs for treating mild or moderate disease activity. Intravenous pulse cyclophosphamide is safer than other regimens and at least as effective as oral cyclophosphamide for severe lupus nephritis. It is also effective in the treatment of central nervous disease and of other organ-threatening manifestations. Recently, an intensified protocol which included cyclophosphamide induced long term treatment-free remission in 60% of patients. The toxicity of cyclophosphamide is considerable, but can be ameliorated by various measures. The value of several new immunosuppressants and other compounds remains to be determined.